The nicotine metabolite ratio is associated with early smoking abstinence even after controlling for factors that influence the nicotine metabolite ratio

Nicotine and Tobacco Research

Volumn 18, Issue 4, 2016, Pages 491-495

  Chenoweth, Meghan J ^a,b   Schnoll, Robert A ^c   Novalen, Maria ^a,b   Hawk, Larry W ^d   George, Tony P ^a,b   Cinciripini, Paul M ^e   Lerman, Caryn ^c   Tyndale, Rachel F ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2A6; ESTROGEN; NICOTINE; NICOTINE PATCH; VARENICLINE; NICOTINE GUM;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; ETHNICITY; FEMALE; GENETIC VARIABILITY; HUMAN; MALE; METABOLITE; NICOTINE METABOLITE RATIO; PREDICTIVE VALUE; PREDICTOR VARIABLE; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; SMOKING CESSATION; TOBACCO CONSUMPTION; TOBACCO DEPENDENCE; METABOLISM; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR; TOBACCO USE DISORDER;

ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINE; PROSPECTIVE STUDIES; SMOKING; SMOKING CESSATION; TIME FACTORS; TOBACCO USE CESSATION PRODUCTS; TOBACCO USE DISORDER; VARENICLINE;

EID: 84963799661     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntv125     Document Type: Article

References (24)

1. Reid JL, Hammond D, Rynard VL, Burkhalter R. Tobacco Use in Canada:Patterns and Trends, 2014 Edition. Waterloo, ON: Propel Centre for Population Health Impact, University of Waterloo; 2014. http://tobaccoreport. ca/2014/TobaccoUseinCanada_2014.pdf. Accessed February 27, 2015.
2. Agaku IT, King BA, Dube SR. Current cigarette smoking among adults-United States, 2005-2012. MMWR Morb Mortal Wkly Rep. 2014;63(2):29-34. www.cdc.gov/mmwr/preview/mmwrhtml/mm6302a2. htm. Accessed February 27, 2015.
3. Ashare RL, Wileyto EP, Perkins KA, Schnoll RA. The first 7 days of a quit attempt predicts relapse: validation of a measure for screening medications for nicotine dependence. J Addict Med. 2013;7(4):249-254. doi: 10.1097/ ADM.0b013e31829363e1.
4. Perkins KA, Lerman C. Early human screening of medications to treat drug addiction: novel paradigms and the relevance of pharmacogenetics. Clin Pharmacol Ther. 2011;89(3):460-463. doi: 10.1038/clpt.2010.254.
5. Perkins KA, Stitzer M, Lerman C. Medication screening for smoking cessation:a proposal for new methodologies. Psychopharmacology (Berl). 2006;184(3-4):628-636. http://link.springer.com/article/10.1007%2Fs00213-005-0105-5. Accessed February 27, 2015.
6. Perkins KA, Lerman C. An efficient early phase 2 procedure to screen medications for efficacy in smoking cessation. Psychopharmacology (Berl). 2014;231(1):1-11. doi: 10.1007/s00213-013-3364-6.
7. Nakajima M, Yamamoto T, Nunoya K, et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos. 1996;24(11):1212-1217. http://dmd.aspetjournals.org/content/ 24/11/1212.long. Accessed February 27, 2015.
8. Nakajima M, Yamamoto T, Nunoya K, et al. Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther. 1996;277(2):1010-1015. http://jpet.aspetjournals. org/content/277/2/1010.long. Accessed February 27, 2015.
9. Dempsey D, Tutka P, Jacob P III, et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther. 2004;76(1):64-72. http://onlinelibrary.wiley.com/doi/10.1016/j. clpt.2004.02.011/abstract. Accessed February 27, 2015.
10. St Helen G, Novalen M, Heitjan DF, et al. Reproducibility of the nicotine metabolite ratio in cigarette smokers. Cancer Epidemiol Biomarkers Prev. 2012;21(7):1105-1114. doi: 10.1158/1055-9965.EPI-12-0236.
11. Bough KJ, Lerman C, Rose JE, et al. Biomarkers for smoking cessation. Clin Pharmacol Ther. 2013;93(6):526-538. doi: 10.1038/clpt.2013.57.
12. Patterson F, Schnoll RA, Wileyto EP, et al. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther. 2008;84(3):320-325. doi: 10.1038/ clpt.2008.57.
13. Schnoll RA, Patterson F, Wileyto EP, et al. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav. 2009;92(1):6-11. doi: 10.1016/j. pbb.2008.10.016.
14. Lerman C, Tyndale R, Patterson F, et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther. 2006;79(6):600-608. http://onlinelibrary.wiley.com/doi/10.1016/j. clpt.2006.02.006/abstract. Accessed February 27, 2015.
15. Chenoweth MJ, Novalen M, Hawk LW Jr, et al. Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers. Cancer Epidemiol Biomarkers Prev. 2014;23(9):1773-1782. doi: 10.1158/1055-9965.EPI-14-0427.
16. Schnoll RA, George TP, Hawk L, et al. The relationship between the nicotine metabolite ratio and three self-report measures of nicotine dependence across sex and race. Psychopharmacology (Berl). 2014;231(12):2515-2523. doi: 10.1007/s00213-013-3421-1.
17. Sofuoglu M, Herman AI, Nadim H, Jatlow P. Rapid nicotine clearance is associated with greater reward and heart rate increases from intravenous nicotine. Neuropsychopharmacology. 2012;37(6):1509-1516. doi: 10.1038/npp.2011.336.
18. Lerman C, Schnoll RA, Hawk LW Jr, et al. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebocontrolled trial. Lancet Respir Med. 2015;3(2):131-138. doi: 10.1016/ S2213-2600(14)70294-2.
19. Ho MK, Mwenifumbo JC, Al Koudsi N, et al. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther. 2009;85(6):635-643. doi: 10.1038/clpt.2009.19.
20. Perkins KA. Nicotine discrimination in men and women. Pharmacol Biochem Behav. 1999;64(2):295-299. www.sciencedirect.com/science/article/pii/S0091305799000854. Accessed February 27, 2015.
21. Hymowitz N, Cummings KM, Hyland A, et al. Predictors of smoking cessation in a cohort of adult smokers followed for five years. Tob Control. 1997;6(suppl 2):S57-62. http://tobaccocontrol.bmj.com/content/6/ suppl_2/S57.full.pdf+html?sid=4a133da5-f7d9-4a7b-9ff8-b76ca3d6e9a6. Accessed February 27, 2015.
22. Osler M, Prescott E, Godtfredsen N, Hein HO, Schnohr P. Gender and determinants of smoking cessation: a longitudinal study. Prev Med. 1999;29(1):57-62. www.sciencedirect.com/science/article/pii/S0091743599905108. Accessed February 27, 2015.
23. Stahre M, Okuyemi KS, Joseph AM, Fu SS. Racial/ethnic differences in menthol cigarette smoking, population quit ratios and utilization of evidence-based tobacco cessation treatments. Addiction. 2010;105(suppl s1):75-83. doi: 10.1111/j.1360-0443.2010.03200.x.
24. Blot WJ, Cohen SS, Aldrich M, et al. Lung cancer risk among smokers of menthol cigarettes. J Natl Cancer Inst. 2011;103(10):810-816. doi: 10.1093/jnci/djr102.